University of Illinois at Chicago
uic.eduTotal trials
502
Active
162
Phase 3
15
Total enrollment
360,122
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 58 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Metformin | — | — | — | — | — | 1 | |
| Abemaciclib | — | — | — | — | — | 1 | |
| Granisetron Transdermal Patch | — | — | — | — | — | 1 | |
| Intravenous Dexamethasone | — | — | — | — | — | 1 | |
| Ondansetron | — | — | — | — | — | 1 | |
| Flecainide | — | — | — | — | — | 1 | |
| Sotalol | — | — | — | — | — | 1 | |
| Deferoxamine | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | 6 | ||
| Fludarabine | — | — | — | — | — | 4 | |
| Paclitaxel | — | — | — | — | 4 | ||
| Methotrexate | — | — | — | — | 3 | ||
| Busulfan | — | — | — | — | — | 3 | |
| Pembrolizumab | — | — | — | — | 2 | ||
| Sirolimus | — | — | — | — | — | 2 | |
| ATG | — | — | — | — | 3 | ||
| Docetaxel | — | — | — | — | 2 | ||
| carboplatin | — | — | — | — | 2 | ||
| Mesenchymal Stromal Cells | — | — | — | — | — | 1 | |
| Glycyrrhizin - 75 mg | — | — | — | — | — | 1 | |
| Glycyrrhizin - 150 mg | — | — | — | — | — | 1 | |
| FIM intervention arm | — | — | — | — | — | 1 | |
| FIM Usual Care Arm | — | — | — | — | — | 1 | |
| Nab-paclitaxel | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome | — | — | — | — | — | 1 | |
| Empagliflozin | — | — | — | — | — | 1 | |
| Isatuximab | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| Neoadjuvant chemotherapy | — | — | — | — | — | 1 | |
| Olanzapine | — | — | — | — | — | 1 | |
| Conditioning regimen with half-matched (haploidentical) stem cell transplant | — | — | — | — | — | 1 | |
| Aromatase Inhibitors | — | — | — | — | — | 1 | |
| Bupropion | — | — | — | — | — | 1 | |
| GnRH agonist | — | — | — | — | — | 1 | |
| mycophenolate mofetil | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| Lactobacillus sakei proBio65 | — | — | — | — | — | 1 | |
| Alemtuzumab | — | — | — | — | — | 1 |
18 more active programs hidden
Next readouts
- 2021-05-05
- 2025-06
- 2025-11-08
- 2026-02-02
- 2026-03
- 2026-03-15
- 2026-03-31
- 2026-04
- 2026-05
- 2026-05
Top conditions
- Obesity28
- Depression22
- Multiple Sclerosis13
- Breast Cancer11
- Stroke11
- Sickle Cell Disease11
- Prostate Cancer10
- Anxiety10
Frequently asked questions about University of Illinois at Chicago
- How many clinical trials does University of Illinois at Chicago have on ClinicalTrials.gov?
- University of Illinois at Chicago is listed as the lead sponsor on 502 clinical trials in ClinicalTrials.gov, 162 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Illinois at Chicago's trials are in Phase 3?
- 15 of University of Illinois at Chicago's trials are in Phase 3, spread across 58 active drug programs.
- What therapeutic areas does University of Illinois at Chicago focus on?
- University of Illinois at Chicago's most-studied conditions on ClinicalTrials.gov are Obesity, Depression, Multiple Sclerosis, Breast Cancer, Stroke.
- When are University of Illinois at Chicago's next clinical trial readouts?
- University of Illinois at Chicago has 10 upcoming primary-completion readouts tracked here; the soonest is “Convalescent Plasma as a Possible Treatment for COVID-19”, expected around 2021-05-05.